Join Troutman Pepper Locke attorneys EA Weeks, Judy O’Grady, and Heather Ettinger for a webinar exploring how the explosive growth of cell and gene therapy (CGT) is reshaping the way life sciences companies structure licensing and collaboration arrangements—in ways that are distinct from traditional small molecule and biologic deals. The discussion will focus on how CGTs’ unique scientific and commercial realities—such as personalized treatment models, complex manufacturing, and evolving intellectual property frameworks—are driving new approaches to contract terms, regulatory strategy, and IP ownership that diverge from conventional paradigms. The panel will also offer practical guidance on how to allocate risk and position CGT collaborations for successful commercialization in this rapidly evolving landscape.

The training is approved for credit in California, Connecticut (through reciprocity), Illinois, Nebraska, Nevada, New Jersey (through reciprocity), New York, North Carolina, Pennsylvania, Rhode Island and Texas. Credit for other jurisdictions may be available upon request. For more information, please email CLE Management.